Akeso, Inc. (FRA:4RY)

Germany flag Germany · Delayed Price · Currency is EUR
13.50
+0.20 (1.50%)
Last updated: Dec 5, 2025, 9:59 AM CET
60.71%
Market Cap 12.62B
Revenue (ttm) 298.43M
Net Income (ttm) -100.56M
Shares Out n/a
EPS (ttm) -0.11
PE Ratio n/a
Forward PE 262.38
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 160
Open 13.50
Previous Close 13.30
Day's Range 13.50 - 13.50
52-Week Range 6.75 - 19.30
Beta n/a
RSI 54.76
Earnings Date Nov 26, 2025

About Akeso

Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat my... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 3,035
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 4RY
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.